Edward C. Parsons

Edward C. Parsons

Auto-generated profile, based on publicly available information

Edward C. Parsons

CXL Ophthalmics, LLC, Encinitas, CA, USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2008 in European Journal of Radiology
Verified
Journal Article
Closed access
RMRobert McGregor
Robert McGregor
JVJosef Vymazal
Josef Vymazal
MMManuel Martinez-Lopez
Manuel Martinez-Lopez
JNJiri Neuwirth
Jiri Neuwirth
PSPerla Salgado
Perla Salgado
EPEdward C. Parsons
Edward C. Parsons

1 January 2021 in Clinical Ophthalmology
Verified
Journal Article
Open access
PDF file
RRRoy S Rubinfeld
Roy S Rubinfeld
GGGlenwood G Gum
Glenwood G Gum
JTJonathan H Talamo
Jonathan H Talamo
EPEdward C Parsons
Edward C Parsons
Purpose: To evaluate effects of sodium iodide (NaI) on riboflavin concentration in corneal stroma before and during ultraviolet A (UVA) light exposure using a novel transepithelial corneal collagen crosslinking (CXL) procedure (EpiSmart CXL system, CXL Ophthalmics, Encinitas CA). Methods: Riboflavin solutions with NaI (Ribostat, CXL Ophthalmics, Encinitas CA) and without NaI were used for CXL in rabbits using EpiSmart. A pilot study determined sufficient riboflavin loading time. Four rabbits were dosed and monitored. Riboflavin fluorescence intensity was assessed from masked slit-lamp photos. A 12 min loading time was selected. Sixteen additional rabbits received the two formulae in contralateral eyes for CXL. Riboflavin uptake was assessed at 0, 10, 15, 20, 25, and 30 min of UVA exposure using a scale for riboflavin fluorescence previously validated against stromal concentration. Post sacrifice, corneal stromal samples were analyzed for concentrations of riboflavin and riboflavin 5'-phosphate. Results: Eyes dosed with NaI riboflavin had higher riboflavin grades compared to eyes dosed with the NaI-free riboflavin formulation immediately after riboflavin loading and persisting throughout UVA exposure, with significantly higher (P < 0.01 to < 0.05) riboflavin grades from 15 through 25 min of UVA exposure. Riboflavin grades decreased more slowly in eyes dosed with NaI riboflavin through 25 minutes of UVA exposure. Minor conjunctival irritation was noted with or without NaI. Conclusion: The addition of NaI to riboflavin solution is associated with increased riboflavin concentration in corneal stroma throughout a clinically relevant time course of UVA exposure. This effect may be a combination of enhanced epithelial penetration and reduced riboflavin photodegradation and should enhance intrastromal crosslinking.

1 January 2022 in Clinical Ophthalmology
Verified
Journal Article
Open access
PDF file
NVNeel S Vaidya
Neel S Vaidya
ADArvin Daneshmand
Arvin Daneshmand
RERandy J Epstein
Randy J Epstein
PMParag A Majmudar
Parag A Majmudar
MBMichael W Belin
Michael W Belin
RRRoy S Rubinfeld
Roy S Rubinfeld
Purpose: To assess the change in corneal pachymetry after a novel epithelium-on (EpiSmart (R)) corneal crosslinking procedure (CXL). Methods: Eyes treated as part of the open-label, non-controlled arm of the study "Collagen Crosslinking with Ultraviolet-A in Asymmetric Corneas" (NCT01097447) were examined at baseline, 3-, 6- and 12-months post-CXL. Thinnest pachymetry readings based on Pentacam (OCULUS GmbH, Wetzlar, Germany) were recorded. Results: A total of 101 eyes met the study inclusion criteria. Thinnest pachymetric readings at baseline averaged 451 +/- 50 microns. The mean (+/- SD) minimum thickness was 450 +/- 46 microns at 3 months, 452 +/- 47 microns at 6 months, and 451 +/- 48 microns at 12 months post-CXL. The changes from baseline (mean +/- SE) at 3, 6, and 12 months post-CXL were -1.2 +/- 1.5 microns, 0.5 +/- 1.6 microns, and 0.4 +/- 1.6 microns, respectively. Student's t-tests showed no statistically significant change in pachymetry from baseline for any exam period. Conclusion: This study demonstrated that, after EpiSmart (R) epithelium-on CXL, there was no substantial corneal thinning observable on Scheimpflug tomography out to 12 months.

1 March 2021 in Clinical Ophthalmology
Verified
Journal Article
Open access
PDF file
MSMazen M Sinjab
Mazen M Sinjab
RRRoy S Rubinfeld
Roy S Rubinfeld
KWKirsten Wagner
Kirsten Wagner
EPEdward C Parsons
Edward C Parsons
ACArthur Bernard Cummings
Arthur Bernard Cummings
MBMichael W Belin
Michael W Belin
Purpose: To assess the effectiveness of a novel treatment for patients with advanced corneal ectasia and loss of visual acuity (VA). Conductive keratoplasty (CK) is performed to improve VA followed by epithelium-on (epi-on) corneal crosslinking (CXL) to stabilize the cornea after CK. Methods: Retrospective, exploratory cohort study. Patients with keratoconus or postsurgical ectasia and best spectacle-corrected distance VA (CDVA) ≤ 20/40 were included. Conductive keratoplasty was performed (ViewPoint CK System, Refractec, Inc., Bloomington, MN); followed a day later by epi-on CXL (CXLUSA/CXLO, Bethesda, MD/CXLO Encinitas, CA). Measures included uncorrected distance visual acuity (UDVA) and CDVA, as well as refractive and tomographic measures and tomographic indices. Results: Data from 50 eyes of 45 patients were analyzed. Mean follow-up was 15.1 ± 12.2 months (range: 2 to 51). Overall, UDVA and CDVA improved postoperatively. Subjective refraction and tomographic metrics did not show consistent changes, but changes in tomographic indices were associated with treatment follow-up time. At the 1-year visit, mean UDVA significantly improved over baseline (P = 0.009) by approximately 3 lines; mean CDVA improved significantly (P = 10− 5) by approximately 2 lines. No eye lost lines of CDVA. Change in the Index of Surface Variance (ISV) was associated with treatment, and the D-Index trended over follow-up time. Conclusion: Conductive keratoplasty with a proprietary epi-on CXL treatment improved vision in patients with advanced ectasia This CK/epi-on CXL treatment offers the possibility of improved VA for patients with compromised vision due to ectasia.